Detailed audit of phishing trading academy: Pig Butchering, Infinite Approval, Kali Linux scanning. Learn how to expose infrastructure and submit Abuse-report. For security developers.
Phosh 0.54 Review: indicator plugins, Phoc improvements, Pixel 6a support and Rust bindings. For middle/senior dev: update and dependency details. Study the release.
Learn how hackers deceive developers through Slack and fake certificates. Analysis of attacks, protection and consequences for Open Source. Read security tips right now.
Technical Analysis of Phishing Attack in Telegram via Fake Contests. IOC, Redirect Chain, Scripts. Protect Accounts: Instructions for Developers. Learn How to Block.
Gedatolisib met the endpoint in the VIKTORIA-1 study, surpassing the standard of care. Learn how this will change the market. Read the detailed analysis.
First ever successful phase 3 in vivo gene editing: lonvo-z therapy reduces HAE attacks by 87%. Learn about the breakthrough and discontinuation of prophylaxis.
FDA approved phase 3 trials of iSCIB1+ DNA vaccine against melanoma. Survival increase of 24%. Find out when the drug will be available and who it will help.
FDA and EMA approved skipping Phase 3 for Herceptin biosimilar AP063. Learn how this decision will change the biosimilar market and accelerate access to cancer therapy.
Interim Results of TELIGAN: Telitacicept Reduces Proteinuria by 58.9% vs 8.8% Placebo. Learn How the New Dual Inhibitor Is Changing the IgA Nephropathy Market.
Intellia presented long-awaited phase III data of CRISPR therapy lonvo-z for hereditary angioedema: 87% reduction in attacks, 62% of patients attack-free. Learn about the breakthrough in in vivo genome editing.
Intellia presented the long-awaited results of phase 3 of CRISPR therapy lonvoguran ziclumeran for hereditary angioedema. Reduction of attacks by 87%, 62% of patients without therapy. Learn more.
Personalized mRNA vaccine showed 42% 18-month recurrence-free survival in glioblastoma. Learn details of the breakthrough JAMA study and prospects of the method.
Analysis of IMP761 data from Immutep at EULAR 2026: a new class of drugs for treating rheumatoid arthritis without total immunosuppression. Safety, mechanism, and prospects. Read more.